Vital Therapies Announces VTL-308 Reaches Enrollment Target of 150 Subjects
22 mars 2018 08h01 HE
|
Vital Therapies, Inc.
SAN DIEGO, March 22, 2018 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver...
Vital Therapies Announces Fourth Quarter and Full Year 2017 Financial Results
13 mars 2018 16h01 HE
|
Vital Therapies, Inc.
- VTL-308 Enrollment Nears Completion with 147 Subjects Enrolled as of March 12- On Track for Release of Topline Results in Third Quarter of 2018 SAN DIEGO, March 13, 2018 (GLOBE NEWSWIRE) --...
Vital Therapies Announces Upcoming Fourth Quarter and Full Year Financial Results Conference Call with Webcast and Participation in Upcoming Conference
27 févr. 2018 07h59 HE
|
Vital Therapies, Inc.
SAN DIEGO, Feb. 27, 2018 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver...
Vital Therapies Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
05 janv. 2018 08h01 HE
|
Vital Therapies, Inc.
SAN DIEGO, Jan. 05, 2018 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver...
Vital Therapies Added to NASDAQ Biotechnology Index
11 déc. 2017 08h00 HE
|
Vital Therapies, Inc.
SAN DIEGO, Dec. 11, 2017 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver...
Vital Therapies Appoints Russell J. Cox as Chief Executive Officer and Board Member Effective January 3, 2018
04 déc. 2017 16h29 HE
|
Vital Therapies, Inc.
SAN DIEGO, Dec. 04, 2017 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver...
Vital Therapies to Webcast Presentation at Upcoming Investor Conference
08 nov. 2017 08h01 HE
|
Vital Therapies, Inc.
SAN DIEGO, Nov. 08, 2017 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver...
Vital Therapies Announces Third Quarter 2017 Financial Results
25 oct. 2017 16h01 HE
|
Vital Therapies, Inc.
SAN DIEGO, Oct. 25, 2017 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver...
Vital Therapies Announces Upcoming Third Quarter Financial Results Conference Call With Webcast
18 oct. 2017 08h01 HE
|
Vital Therapies, Inc.
SAN DIEGO, Oct. 18, 2017 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver...
Vital Therapies Announces Recent and Upcoming Scientific Presentations and Participation in Upcoming Investor Conference
11 sept. 2017 08h01 HE
|
Vital Therapies, Inc.
SAN DIEGO, Sept. 11, 2017 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver...